{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:22:19Z","timestamp":1791134539469,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.sleep.2007.03.004","type":"journal-article","created":{"date-parts":[[2007,5,2]],"date-time":"2007-05-02T14:37:24Z","timestamp":1178116644000},"page":"427-440","source":"Crossref","is-referenced-by-count":56,"title":["Therapeutic advances in narcolepsy"],"prefix":"10.1016","volume":"8","author":[{"given":"Michael","family":"Thorpy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2007.03.004_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00023210-199605060-00003","article-title":"Narcolepsy. Current drug treatment options","volume":"5","author":"Hublin","year":"1996","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2007.03.004_bib2","doi-asserted-by":"crossref","unstructured":"U.S. Modafinil in Narcolepsy Multicenter Study Group: randomized trial of modafinil as a treatment for excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166\u201375.","DOI":"10.1212\/WNL.54.5.1166"},{"key":"10.1016\/j.sleep.2007.03.004_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00004691-200103000-00002","article-title":"Narcolepsy: clinical features, new pathological insights, and future perspectives","volume":"18","author":"Overeem","year":"2001","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.sleep.2007.03.004_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1389-9457(00)00081-2","article-title":"Current concepts in the etiology, diagnosis and treatment of narcolepsy","volume":"2","author":"Thorpy","year":"2001","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2007.03.004_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1176\/appi.neuropsych.17.1.45","article-title":"Characterizing the emotions that trigger cataplexy","volume":"17","author":"Krahn","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"Suppl. 1","key":"10.1016\/j.sleep.2007.03.004_bib6","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1212\/WNL.50.2_Suppl_1.S16","article-title":"Genetic and familial aspects of narcolepsy","volume":"50","author":"Mignot","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2007.03.004_bib7","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.58.12.1826","article-title":"Prevalence of narcolepsy symptomatology and diagnosis in the European general population","volume":"58","author":"Ohayan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2007.03.004_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.sleep.2003.06.002","article-title":"Factors associated with a delay in the diagnosis of narcolepsy","volume":"5","author":"Morrish","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2007.03.004_bib9","series-title":"Narcolepsy","first-page":"179","article-title":"The evolution of narcolepsy with age","author":"Passouant","year":"1976"},{"issue":"8 Suppl.","key":"10.1016\/j.sleep.2007.03.004_bib10","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/sleep\/17.suppl_8.S45","article-title":"Psychosocial impact of narcolepsy","volume":"17","author":"Broughton","year":"1994","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.sleep.2004.04.003","article-title":"Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey","volume":"5","author":"Vignatelli","year":"2004","journal-title":"Sleep Medicine"},{"issue":"8 Suppl.","key":"10.1016\/j.sleep.2007.03.004_bib12","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1093\/sleep\/17.suppl_8.S84","article-title":"Neuropharmacology and neurochemistry of canine narcolepsy","volume":"17","author":"Nishino","year":"1994","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.sleep.2007.03.004_bib13","first-page":"598","article-title":"Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem","volume":"17","author":"Aldrich","year":"1994","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2007.03.004_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0987-7053(05)80281-3","article-title":"Autoradiographic studies of post-mortem human narcoleptic brain","volume":"23","author":"Aldrich","year":"1993","journal-title":"Neurophysiol Clin"},{"issue":"2","key":"10.1016\/j.sleep.2007.03.004_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1212\/WNL.42.2.410","article-title":"Dopamine-receptor autoradiography of human narcoleptic brain","volume":"42","author":"Aldrich","year":"1992","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene [see comments]","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation [see comments]","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"issue":"9197","key":"10.1016\/j.sleep.2007.03.004_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.sleep.2007.03.004_bib19","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1212\/01.WNL.0000168173.71940.ab","article-title":"Concomitant loss of dynorphin, NARP, and orexin in narcolepsy","volume":"65","author":"Crocker","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib20","first-page":"352","article-title":"Narcolepsy and its treatment with stimulants","volume":"17","author":"Mitler","year":"1994","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0733-8619(05)70273-5","article-title":"Narcolepsy","volume":"14","author":"Bassetti","year":"1996","journal-title":"Neurol Clin"},{"issue":"6","key":"10.1016\/j.sleep.2007.03.004_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJM199008093230606","article-title":"Narcolepsy","volume":"323","author":"Aldrich","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sleep.2007.03.004_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/sleep\/28.6.667","article-title":"Risks of high dose stimulants in the treatment of disorders of excessive somnolence. A case control study","volume":"28","author":"Auger","year":"2005","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2007.03.004_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/sleep\/20.1.28","article-title":"Compliance with stimulant medications in patients with narcolepsy","volume":"20","author":"Rogers","year":"1997","journal-title":"Sleep"},{"issue":"Suppl.","key":"10.1016\/j.sleep.2007.03.004_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0404.1983.tb01517.x","article-title":"Deprenyl (selegiline): the history of its development and pharmacological action","volume":"95","author":"Knoll","year":"1983","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00002826-199508000-00002","article-title":"Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study","volume":"18","author":"Mayer","year":"1995","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.sleep.2007.03.004_bib27","first-page":"362","article-title":"REM changes in narcolepsy with selegiline","volume":"18","author":"Reinish","year":"1995","journal-title":"Sleep"},{"issue":"11","key":"10.1016\/j.sleep.2007.03.004_bib28","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/WNL.44.11.2095","article-title":"Selegiline in the treatment of narcolepsy","volume":"44","author":"Hublin","year":"1994","journal-title":"Neurology"},{"issue":"6 Pt 2","key":"10.1016\/j.sleep.2007.03.004_bib29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/clpt.1994.205","article-title":"Therapy with l-deprenyl (selegiline) and relation to abuse liability","volume":"56","author":"Schneider","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.sleep.2007.03.004_bib30","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0006-3223(97)00353-3","article-title":"Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers","volume":"42","author":"Ferraro","year":"1997","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/BF02247379","article-title":"Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil","volume":"126","author":"Gold","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF00176625","article-title":"Inhibitory effects of the psychoactive drug modafinil on gamma- aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms","volume":"345","author":"Tanganelli","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.sleep.2007.03.004_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(96)13212-2","article-title":"The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor","volume":"220","author":"Ferraro","year":"1996","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0893-133X(98)00085-2","article-title":"The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade","volume":"20","author":"Ferraro","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.sleep.2007.03.004_bib35","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1523\/JNEUROSCI.21-05-01787.2001","article-title":"Dopaminergic role in stimulant-induced wakefulness","volume":"21","author":"Wisor","year":"2001","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib36","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroscience.2005.02.003","article-title":"Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil","volume":"132","author":"Wisor","year":"2005","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.sleep.2007.03.004_bib37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/sleep\/17.5.436","article-title":"Modafinil binds to the dopamine uptake carrier site with low affinity","volume":"17","author":"Mignot","year":"1994","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib38","first-page":"183","article-title":"Differential effects of a new central adrenergic agonist\u2013modafinil\u2013 and d-amphetamine on sleep and early morning behaviour in young healthy volunteers","volume":"9","author":"Saletu","year":"1989","journal-title":"Int J Clin Pharmacol Res"},{"issue":"2","key":"10.1016\/j.sleep.2007.03.004_bib39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.49.2.444","article-title":"Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy","volume":"49","author":"Broughton","year":"1997","journal-title":"Neurology"},{"issue":"8 Suppl.","key":"10.1016\/j.sleep.2007.03.004_bib40","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/sleep\/17.suppl_8.S107","article-title":"Modafinil: a double-blind multicentric study","volume":"17","author":"Billiard","year":"1994","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2007.03.004_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00002826-199302000-00005","article-title":"Effects of modafinil on symptomatology of human narcolepsy","volume":"16","author":"Boivin","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib42","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998;43(1):88\u201397.","DOI":"10.1002\/ana.410430115"},{"key":"10.1016\/j.sleep.2007.03.004_bib43","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000;54(5):1166\u201375.","DOI":"10.1212\/WNL.54.5.1166"},{"key":"10.1016\/j.sleep.2007.03.004_bib44","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/sleep\/5.S2.S107","article-title":"Daytime sleepiness and daytime wakefulness: the effect of instruction","volume":"5","author":"Hartse","year":"1982","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/sleep\/15.3.268","article-title":"The clinical use of the Multiple Sleep Latency Test","volume":"15","author":"Thorpy","year":"1992","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archinte.163.5.565","article-title":"Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis","volume":"163","author":"Patel","year":"2003","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1389-9457(00)00031-9","article-title":"Long-term efficacy and safety of modafinil (Provigil) for the treatment of excessive daytime sleepiness associated with narcolepsy","volume":"1","author":"Mitler","year":"2000","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2007.03.004_bib48","first-page":"451","article-title":"Practice parameters for the treatment of narcolepsy: an update for 20 00","volume":"24","author":"Littner","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0987-7053(96)81535-8","article-title":"Use of modafinil in the treatment of narcolepsy: a long term follow-up study","volume":"26","author":"Besset","year":"1996","journal-title":"Neurophysiol Clin"},{"issue":"8 Suppl.","key":"10.1016\/j.sleep.2007.03.004_bib50","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/sleep\/17.suppl_8.S107","article-title":"Modafinil: a double-blind multicentric study","volume":"17","author":"Billiard","year":"1994","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib51","doi-asserted-by":"crossref","unstructured":"U.S. Xyrem\u00ae International Study Group: a double blind placebo controlled study demonstates sodium oxybate is effective for the treatment of excessive sleepiness in narcolepsy. J Clin Sleep Med 2005; 1(4):391\u2013397. 704\u20136.","DOI":"10.5664\/jcsm.26368"},{"issue":"Suppl.","key":"10.1016\/j.sleep.2007.03.004_bib52","first-page":"A57","article-title":"Postmarketing surveillance of modafinil abuse and misuse (abstract)","volume":"27","author":"Smith","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00008877-200203000-00002","article-title":"Acute behavioral and physiological effects of modafinil in drug abusers","volume":"13","author":"Rush","year":"2002","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00002826-200005000-00004","article-title":"Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy","volume":"23","author":"Jasinski","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002826-200309000-00009","article-title":"Dosing regimen effects of narcolepsy for improving daytime wakefulness in patients with narcolepsy","volume":"26","author":"Schwartz","year":"2003","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1176\/appi.neuropsych.17.3.405","article-title":"Dose response and dose regimen effects of modafinil in sustaining daytime wakefulness in narcolepsy patients with residual excessive sleepiness","volume":"17","author":"Schwartz","year":"2005","journal-title":"J Neurol Clin Neurosci J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.sleep.2007.03.004_bib57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/jnnp.72.2.179","article-title":"Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study","volume":"72","author":"Rammohan","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.sleep.2007.03.004_bib58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1185\/030079906X80378","volume":"22","author":"Dinges","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.sleep.2007.03.004_bib59","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1210\/jcem-44-5-1014","article-title":"Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans","volume":"44","author":"Takahara","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.sleep.2007.03.004_bib60","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1592\/phco.21.20.1486.34472","article-title":"A comprehensive review of MDMA and GHB: two common club drugs","volume":"21","author":"Teter","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.sleep.2007.03.004_bib61","unstructured":"Food and drug administration: gamma hydroxybutyric acid. Press release. Rockville, MD: November 8, 1990."},{"key":"10.1016\/j.sleep.2007.03.004_bib62","doi-asserted-by":"crossref","unstructured":"Centers for disease control: multistate outbreak of poisonings associated with illicit use of gamma hydroxybutyrate. J Am Med Assoc 1991;256:447\u20138.","DOI":"10.1001\/jama.265.4.447"},{"key":"10.1016\/j.sleep.2007.03.004_bib63","unstructured":"Drug enforcement administration: schedules of controlled substances: addition of gamma hydroxybutyric acid to schedule I. Fed Reg 2000;65:13235\u20138."},{"key":"10.1016\/j.sleep.2007.03.004_bib64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0028-3908(64)90074-7","article-title":"Sodium 4-hydroxybutyrate","volume":"3","author":"Laborit","year":"1964","journal-title":"Int J Neuropharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib65","first-page":"273","article-title":"The effects of gamma-hydroxybutyrate on sleep","volume":"12","author":"Mamelak","year":"1977","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.sleep.2007.03.004_bib66","first-page":"23","article-title":"Effects of nocturnal gamma-hydroxybutyrate on sleep\/waking patterns in narcolepsy-cataplexy","volume":"7","author":"Broughton","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.sleep.2007.03.004_bib67","first-page":"222","article-title":"The effects and effectiveness of \u03b3-hydroxybutyrate in patients with narcolepsy","volume":"46","author":"Scharf","year":"1985","journal-title":"J Clin Psych"},{"key":"10.1016\/j.sleep.2007.03.004_bib68","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-3223(89)90048-6","article-title":"Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures","volume":"26","author":"Scrima","year":"1989","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.sleep.2007.03.004_bib69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/sleep\/13.6.479","article-title":"The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study","volume":"13","author":"Scrima","year":"1990","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/sleep\/16.3.216","article-title":"Gamma-hydroxybutyrate and narcolepsy: a double- blind placebo-controlled study","volume":"16","author":"Lammers","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib71","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0306-3623(92)90282-O","article-title":"Significance of \u03b3-hydroxybutyric acid in the brain","volume":"23","author":"Tunnicliffe","year":"1992","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0301-0082(96)00064-0","article-title":"The \u03b3-hydroxybutyrate signaling system in brain: organization and functional implications","volume":"51","author":"Maitre","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.sleep.2007.03.004_bib73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0022-3565(24)37787-0","article-title":"Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons","volume":"287","author":"Madden","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2007.03.004_bib74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/sleep\/21.5.507","article-title":"Pharmacokinetics of gamma-hydroxybutyrate (GHB) in narcoleptic patients","volume":"21","author":"Scharf","year":"1998","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib75","first-page":"1053","article-title":"Xyrem\u00ae (sodium oxybate). A study of dose proportionality in healthy human subjects","volume":"40","author":"Borgen","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0091270002239707","article-title":"The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects","volume":"43","author":"Borgen","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0091270003262795","article-title":"The pharmacokinetics of sodium oxybate following acute and chronic administration to narcoleptic patients","volume":"44","author":"Borgen","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2007.03.004_bib78","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1471-4159.1981.tb04689.x","article-title":"The extraneural distribution of \u03b3-hydroxybutyrate","volume":"37","author":"Nelson","year":"1981","journal-title":"J Neurochem"},{"key":"10.1016\/j.sleep.2007.03.004_bib79","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/BF00965839","article-title":"An overview of gamma-hydroxybutyrate catabolism: the role of the cytosolic NADP(+)-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway","volume":"16","author":"Kaufman","year":"1991","journal-title":"Neurochem Res"},{"key":"10.1016\/j.sleep.2007.03.004_bib80","unstructured":"U.S. Xyrem\u00ae Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25(1):42\u20139."},{"key":"10.1016\/j.sleep.2007.03.004_bib81","unstructured":"U.S. Xyrem\u00ae Multicenter Study Group. A 12-month, open-label, multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26:31\u20135."},{"key":"10.1016\/j.sleep.2007.03.004_bib82","first-page":"704","article-title":"Pharmacotherapy in narcolepsy","volume":"21","author":"Akimoto","year":"1960","journal-title":"Dis Nerv System"},{"key":"10.1016\/j.sleep.2007.03.004_bib83","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0404.1976.tb07621.x","article-title":"Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride","volume":"54","author":"Guilleminault","year":"1976","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.sleep.2007.03.004_bib84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0022-510X(66)90001-3","article-title":"Treatment of narcolepsy with imipramine (Tofranil) and desmethylimipramine (Pertofran)","volume":"3","author":"Hishikawa","year":"1966","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.sleep.2007.03.004_bib85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneur.1974.00490400069008","article-title":"A study on cataplexy","volume":"31","author":"Guilleminault","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sleep.2007.03.004_bib86","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.smrv.2004.01.004","article-title":"Pharmacotherapy for cataplexy","volume":"8","author":"Houghton","year":"2004","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2007.03.004_bib87","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/archneur.1975.00490520023002","article-title":"Treatment of cataplexy with clomipramine","volume":"32","author":"Shapiro","year":"1975","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sleep.2007.03.004_bib88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2869.1995.tb00159.x","article-title":"Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine","volume":"4","author":"Chen","year":"1995","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2007.03.004_bib89","first-page":"113","article-title":"Status cataplecticus induced by abrupt withdrawal of clomipramine","volume":"17","author":"Martinez-Rodriguez","year":"2002","journal-title":"Neurologia"},{"key":"10.1016\/j.sleep.2007.03.004_bib90","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1212\/WNL.44.4.707","article-title":"Fluoxetine suppresses human cataplexy: a pilot study","volume":"44","author":"Frey","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2007.03.004_bib91","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/sleep\/9.2.371","article-title":"Fluoxetine in the treatment of cataplexy","volume":"9","author":"Langdon","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib92","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM197110282851802","article-title":"Treatment of intractable narcolepsy with a monoamine oxidase inhibitor","volume":"285","author":"Wyatt","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sleep.2007.03.004_bib93","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0404.1979.tb02976.x","article-title":"Mazindol in the treatment of narcolepsy","volume":"60","author":"Parkes","year":"1979","journal-title":"Acta Neurol Scand"},{"issue":"1 Pt 2","key":"10.1016\/j.sleep.2007.03.004_bib94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/sleep\/9.1.265","article-title":"Therapeutic effects of mazindol on narcolepsy","volume":"9","author":"Iijima","year":"1986","journal-title":"Sleep"},{"issue":"Suppl. 1","key":"10.1016\/j.sleep.2007.03.004_bib95","first-page":"217","article-title":"Venlafaxine in the treatment of the narcoleptic syndrome","volume":"5","author":"Smith","year":"1996","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2007.03.004_bib96","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-0404.1986.tb03518.x","article-title":"The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo","volume":"74","author":"Schrader","year":"1986","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.sleep.2007.03.004_bib97","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","article-title":"Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study","volume":"24","author":"Larrosa","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib98","doi-asserted-by":"crossref","unstructured":"U.S. Xyrem\u00ae Multicenter Study Group: sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119\u2013123.","DOI":"10.1016\/j.sleep.2003.11.002"},{"key":"10.1016\/j.sleep.2007.03.004_bib99","doi-asserted-by":"crossref","unstructured":"Xyrem\u00ae International Study Group: further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 2228 patients. Sleep Med 2005;6:415\u201321.","DOI":"10.1016\/j.sleep.2005.03.010"},{"key":"10.1016\/j.sleep.2007.03.004_bib100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00139709-200423010-00005","article-title":"The gamma-hydroxybutyrate withdrawal syndrome","volume":"23","author":"Tarabar","year":"2004","journal-title":"Toxicol Rev"},{"issue":"7","key":"10.1016\/j.sleep.2007.03.004_bib101","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/sleep\/27.7.1327","article-title":"A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy","volume":"27","author":"Mamelak","year":"2004","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib102","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/sleep\/15.3.212","article-title":"Short-term triazolam use improves nocturnal sleep of narcoleptics","volume":"15","author":"Thorpy","year":"1992","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib103","series-title":"Narcolepsy","first-page":"625","article-title":"The action of tricyclics (Alone or in combination with methylphenidate) upon several symptoms of narcolepsy","author":"Takahashi","year":"1976"},{"key":"10.1016\/j.sleep.2007.03.004_bib104","series-title":"Narcolepsy","first-page":"125","article-title":"Cataplexy","author":"Guilleminault","year":"1976"},{"issue":"1 Pt 2","key":"10.1016\/j.sleep.2007.03.004_bib105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/sleep\/9.1.285","article-title":"Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings","volume":"9","author":"Mamelak","year":"1986","journal-title":"Sleep"},{"issue":"2 Suppl. 1","key":"10.1016\/j.sleep.2007.03.004_bib106","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1212\/WNL.50.2_Suppl_1.S31","article-title":"The influence of clinical symptoms on quality of life in patients with narcolepsy","volume":"50","author":"Goswami","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.sleep.2007.03.004_bib107_1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/sleep\/22.6.757","article-title":"Health-related quality of life effects of modafinil for treatment of narcolepsy","volume":"22","author":"Beusterien","year":"1999","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib107_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0092-8674(00)81969-8","article-title":"Narcolepsy: a key role for hypocretins (orexins) [comment]","volume":"98","author":"Siegel","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.sleep.2007.03.004_bib108","first-page":"A219","article-title":"Sodium oxybate for narcolepsy improves patient quality of life","volume":"28","author":"Weaver","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2007.03.004_bib109","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/sleep\/28.6.754","article-title":"Emerging therapies in narcolepsy-cataplexy","volume":"28960","author":"Mignot","year":"2005","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.sleep.2007.03.004_bib111","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1523\/JNEUROSCI.19-01-00248.1999","article-title":"Neuronal degeneration in canine narcolepsy","volume":"19","author":"Siegel","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.sleep.2007.03.004_bib112","first-page":"66","article-title":"Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy","volume":"4","author":"Hanson","year":"2004","journal-title":"Drug Delivery Technol"},{"issue":"13","key":"10.1016\/j.sleep.2007.03.004_bib113","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","article-title":"Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice","volume":"101","author":"Mieda","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.sleep.2007.03.004_bib114","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.expneurol.2004.04.006","article-title":"Treatment with immunosuppressive and anti-inflammatory agents delays onsets of canine genetic narcolepsy and reduces symptom severity","volume":"188","author":"Boehmer","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.sleep.2007.03.004_bib115","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1939-1676.2004.tb02590.x","article-title":"Case study: effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy","volume":"18","author":"Schatzberg","year":"2004","journal-title":"J Vet Internal Med"},{"issue":"7","key":"10.1016\/j.sleep.2007.03.004_bib116","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/sleep\/26.7.809","article-title":"Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy","volume":"26","author":"Hecht","year":"2003","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.sleep.2007.03.004_bib117","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.20603","article-title":"Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis","volume":"58","author":"Chen","year":"2005","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.sleep.2007.03.004_bib118","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2869.2003.00380.x","article-title":"Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy","volume":"12","author":"Lecendreux","year":"2003","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2007.03.004_bib119","doi-asserted-by":"crossref","unstructured":"Yves Dauvilliers MD, Bertrand Carlander MD, Fran\u00e7ois Rivier MD, PhD, Jacques Touchon MD, Mehdi Tafti, Ph.D. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56(6):905\u20138.","DOI":"10.1002\/ana.20339"},{"issue":"Suppl. 1","key":"10.1016\/j.sleep.2007.03.004_bib120","first-page":"828","article-title":"Variable response to intravenous immunoglobulin therapy in childhood narcolepsy","volume":"13","author":"Zuberi","year":"2004","journal-title":"J Sleep Res"},{"issue":"2","key":"10.1016\/j.sleep.2007.03.004_bib121","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.expneurol.2004.04.006","article-title":"Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity","volume":"188","author":"Boehmer","year":"2004","journal-title":"Exp Neurol"},{"issue":"16","key":"10.1016\/j.sleep.2007.03.004_bib122","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1523\/JNEUROSCI.17-16-06401.1997","article-title":"Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy","volume":"17","author":"Nishino","year":"1997","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.sleep.2007.03.004_bib123","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0893-133X(99)00159-1","article-title":"Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy","volume":"23","author":"Riehl","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.sleep.2007.03.004_bib124","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1523\/JNEUROSCI.3198-04.2005","article-title":"Excitatory effects of thyrotropin-releasing hormone in the thalamus","volume":"25","author":"Broberger","year":"2005","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.sleep.2007.03.004_bib125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bjp.0705964","article-title":"Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist","volume":"143","author":"Barbier","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.sleep.2007.03.004_bib126","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S0022-3565(24)38248-5","article-title":"Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands","volume":"289","author":"Tedford","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2007.03.004_bib127","first-page":"A241","article-title":"Wake promoting effects of thioperamide, a histamin H3 antagonist in orexin\/ataxin-3 narcoleptic mice","author":"Shiba","year":"2004","journal-title":"Sleep"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945707000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945707000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:26:43Z","timestamp":1736987203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945707000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1389945707000809"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2007.03.004","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}